AR126749A1 - Tratamiento de la dermatitis atópica - Google Patents
Tratamiento de la dermatitis atópicaInfo
- Publication number
- AR126749A1 AR126749A1 ARP220102143A ARP220102143A AR126749A1 AR 126749 A1 AR126749 A1 AR 126749A1 AR P220102143 A ARP220102143 A AR P220102143A AR P220102143 A ARP220102143 A AR P220102143A AR 126749 A1 AR126749 A1 AR 126749A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- treatment
- atopic dermatitis
- antibody
- ox40l
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000012377 drug delivery Methods 0.000 abstract 1
- 239000011521 glass Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a métodos para el tratamiento de la Dermatitis Atópica en un sujeto humano que comprenden administrar una cantidad terapéuticamente eficaz de un anticuerpo anti-OX40L, o fragmento de unión a antígeno del mismo, en donde el anticuerpo o fragmento del mismo se administran mediante inyección. También se proporcionan anticuerpos anti-OX40L, o fragmentos de unión a antígeno de los mismos, viales de vidrio, dispositivos de suministro de fármacos, jeringas precargadas, microinfusores, dispositivos de suministro de tipo pluma, autoinjyectores y kits que comprenden un anticuerpo anti-OX40L, o fragmento de unión a antígeno del mismo para su uso en tales métodos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB202111492 | 2021-08-10 | ||
| GBGB2115152.7A GB202115152D0 (en) | 2021-10-21 | 2021-10-21 | Treatment of atopic dermatitis |
| GBGB2204211.3A GB202204211D0 (en) | 2022-03-24 | 2022-03-24 | Treatment of atopic dermatitis |
| GBGB2204291.5A GB202204291D0 (en) | 2022-03-25 | 2022-03-25 | Treatment of atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126749A1 true AR126749A1 (es) | 2023-11-08 |
Family
ID=82942548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102143A AR126749A1 (es) | 2021-08-10 | 2022-08-09 | Tratamiento de la dermatitis atópica |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230235069A1 (es) |
| EP (1) | EP4384270A1 (es) |
| KR (1) | KR20240043789A (es) |
| AR (1) | AR126749A1 (es) |
| AU (1) | AU2022326849A1 (es) |
| CA (1) | CA3228708A1 (es) |
| IL (1) | IL310701A (es) |
| TW (1) | TW202330023A (es) |
| WO (1) | WO2023017252A1 (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006343459A1 (en) * | 2005-12-16 | 2007-11-22 | Genentech, Inc. | Anti-OX40L antibodies and methods using same |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2011073180A1 (en) * | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN107074951B (zh) * | 2014-08-04 | 2021-08-03 | 贝勒研究院 | 拮抗性抗-ox40l抗体及其使用方法 |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| CN108064169B (zh) | 2015-03-03 | 2022-02-11 | 科马布有限公司 | 抗体、用途和方法 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
-
2022
- 2022-08-09 AR ARP220102143A patent/AR126749A1/es unknown
- 2022-08-09 US US17/818,397 patent/US20230235069A1/en active Pending
- 2022-08-09 TW TW111129825A patent/TW202330023A/zh unknown
- 2022-08-09 EP EP22757333.4A patent/EP4384270A1/en active Pending
- 2022-08-09 KR KR1020247007705A patent/KR20240043789A/ko unknown
- 2022-08-09 CA CA3228708A patent/CA3228708A1/en active Pending
- 2022-08-09 AU AU2022326849A patent/AU2022326849A1/en active Pending
- 2022-08-09 WO PCT/GB2022/052070 patent/WO2023017252A1/en active Application Filing
- 2022-08-09 IL IL310701A patent/IL310701A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023017252A1 (en) | 2023-02-16 |
| AU2022326849A1 (en) | 2024-03-21 |
| US20230235069A1 (en) | 2023-07-27 |
| CA3228708A1 (en) | 2023-02-16 |
| EP4384270A1 (en) | 2024-06-19 |
| TW202330023A (zh) | 2023-08-01 |
| KR20240043789A (ko) | 2024-04-03 |
| IL310701A (en) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021006092A2 (es) | Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas | |
| ECSP17005649A (es) | Anticuerpos anti-tau humanizados | |
| CO2019012151A2 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| PE20190205A1 (es) | Uso de inhibidores de miostatina y terapias de combinacion | |
| BR112018009064A2 (pt) | anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| ECSP13012792A (es) | Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9 | |
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| BR112016003358A2 (pt) | método para aumentar a expressão de proteínas codificadas por rna | |
| DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| EA201991526A1 (ru) | Конъюгаты антитела и лекарственного средства для разрушения гемопоэтических стволовых клеток | |
| AR061669A1 (es) | Aplicacion de alta frecuencia de terapia con toxina botulinica | |
| BR112022000581A2 (pt) | Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r | |
| AR103896A1 (es) | Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3 | |
| AR082390A1 (es) | Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de akt | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| BR112021009856A8 (pt) | Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l | |
| CO2021008665A2 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| MX2022004268A (es) | Cartucho para un autoinyector y metodos relacionados. | |
| AR115721A1 (es) | Anticuerpos que comprenden un polipéptido insertado en la región marco 3 | |
| CL2018000002A1 (es) | Agente terapéutico y método para tratar el síndrome de hunter. | |
| RU2012108108A (ru) | Концентрированные полипептидные лекарственные формы с пониженной вязкостью | |
| AR080188A1 (es) | Tratamiento con un anticuerpo anti-egfr de la clase igg humanizada y con un anticuerpo contra el receptor del factor 1 de crecimiento similar a insulina |